Subtoxic levels of apigenin inhibit expression and secretion of VEGF by uveal melanoma cells via suppression of ERK1/2 and PI3K/AKT pathways

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Chao, Shih Chun ^a,c   Huang, Sheng Chieh ^b   Hu, Dan Ning ^c   Lin, Hung Yu ^a,d  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d YUANPEI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APIGENIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN;

ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA MELANOMA;

EID: 84888598216     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/817674     Document Type: Article

References (38)

1. Hu D. N., Yu G. P., McCormick S. A., Schneider S., Finger P. T., Population-based incidence of uveal melanoma in various races and ethnic groups. American Journal of Ophthalmology 2005 140 4 612 617 2-s2.0-26844447940 10.1016/j.ajo.2005.05.034 (Pubitemid 41455300)
2. Kujala E., Mäkitie T., Kivelä T., Very long-term prognosis of patients with malignant uveal melanoma. Investigative Ophthalmology and Visual Science 2003 44 11 4651 4659 2-s2.0-0142200859 10.1167/iovs.03-0538 (Pubitemid 37315273)
3. Augsburger J. J., Corrêa Z. M., Shaikh A. H., Effectiveness of treatments for metastatic uveal melanoma. American Journal of Ophthalmology 2009 148 1 119 127 2-s2.0-67349216128 10.1016/j.ajo.2009.01.023
4. Xie K., Wei D., Shi Q., Huang S., Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine and Growth Factor Reviews 2004 15 5 297 324 2-s2.0-4344692045 10.1016/j.cytogfr.2004.04.003 (Pubitemid 39140697)
5. Loureiro R. M. B., D'Amore P. A., Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine and Growth Factor Reviews 2005 16 1 77 89 2-s2.0-14044271973 10.1016/j.cytogfr.2005.01.005 (Pubitemid 40279118)
6. Logan P., Burnier J., Burnier M. N. Jr., Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines. Ecancermedicalscience 2013 7 article 336 10.3332/ecancer.2013.336
7. Notting I. C., Missotten G. S. O. A., Sijmons B., Boonman Z. F. H. M., Keunen J. E. E., van der Pluijm G., Angiogenic profile of uveal melanoma. Current Eye Research 2006 31 9 775 785 2-s2.0-33748565945 10.1080/ 02713680600865052 (Pubitemid 44373549)
8. El Filali M., Missotten G. S. O. A., Maat W., Ly L. V., Luyten G. P. M., van der Velden P. A., Jager M. J., Regulation of VEGF-A in uveal melanoma. Investigative Ophthalmology and Visual Science 2010 51 5 2329 2337 2-s2.0-77952509583 10.1167/iovs.09-4739
9. Barak V., Pe'er J., Kalickman I., Frenkel S., VEGF as a biomarker for metastatic uveal melanoma in humans. Current Eye Research 2011 36 4 386 390 2-s2.0-79952760563 10.3109/02713683.2010.534573
10. Shukla S., Gupta S., Apigenin: a promising molecule for cancer prevention. Pharmaceutical Research 2010 27 6 962 978 2-s2.0-77953189137 10.1007/s11095-010-0089-7
11. Patel D., Shukla S., Gupta S., Apigenin and cancer chemoprevention: progress, potential and promise (review). International Journal of Oncology 2007 30 1 233 245 2-s2.0-34248226610
12. Fang J., Xia C., Cao Z., Zheng J. Z., Reed E., Jiang B. H., Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB Journal 2005 19 3 342 353 2-s2.0-14644432362 10.1096/fj.04-2175com (Pubitemid 40316522)
13. Fang J., Zhou Q., Liu L. Z., Xia C., Hu X., Shi X., Jiang B. H., Apigenin inhibits tumor angiogenesis through decreasing HIF-1 and VEGF expression. Carcinogenesis 2007 28 4 858 864 2-s2.0-34047132303 10.1093/carcin/bgl205 (Pubitemid 46523341)
14. Mirzoeva S., Nam D. K., Chiu K., Franzen C. A., Bergan R. C., Pelling J. C., Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Molecular Carcinogenesis 2008 47 9 686 700 2-s2.0-50249087534 10.1002/mc.20421
15. Shukla S., Gupta S., Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clinical Cancer Research 2004 10 9 3169 3178 2-s2.0-2442424073 10.1158/1078-0432.CCR-03-0586 (Pubitemid 38619698)
16. Mafuvadze B., Benakanakere I., López Pérez F. R., Besch-Williford C., Ellersieck M. R., Hyder S. M., Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene- induced mammary tumors in sprague-dawley rats. Cancer Prevention Research 2011 4 8 1316 1324 2-s2.0-80051534217 10.1158/1940-6207.CAPR-10-0382
17. Shukla S., MacLennan G. T., Fu P., Gupta S., Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. Pharmaceutical Research 2012 29 6 1506 1517 2-s2.0-82355170167 10.1007/s11095-011-0625-0
18. Kim B. R., Jeon Y. K., Nam M. J., A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells. Food and Chemical Toxicology 2011 49 7 1626 1632 2-s2.0-79957639518 10.1016/j.fct.2011.04.015
19. Melstrom L. G., Salabat M. R., Ding X. Z., Strouch M. J., Grippo P. J., Mirzoeva S., Pelling J. C., Bentrem D. J., Apigenin down-regulates the hypoxia response genes: HIF-1 GLUT-1, and VEGF in human pancreatic cancer cells. Journal of Surgical Research 2011 167 2 173 181 2-s2.0-79954598113 10.1016/j.jss.2010. 10.041
20. Luo H., Jiang B. H., King S. M., Chen Y. C., Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutrition and Cancer 2008 60 6 800 809 2-s2.0-56249133327 10.1080/01635580802100851
21. Liu L. Z., Fang J., Zhou Q., Hu X., Shi X., Jiang B. H., Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Molecular Pharmacology 2005 68 3 635 643 2-s2.0-23944521126 10.1124/mol.105. 011254 (Pubitemid 41206017)
22. Hu D. N., McCormick S. A., Ritch R., Pelton-Henrion K., Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uveal melanocytes. Investigative Ophthalmology and Visual Science 1993 34 7 2210 2219 2-s2.0-0027197111 (Pubitemid 23191247)
23. Hu D. N., Regulation of growth and melanogenesis of uveal melanocytes. Pigment Cell Research 2000 13 8 81 86 2-s2.0-0034565169
24. Hu D. N., McCormick S. A., Woodward D. F., A functional study on prostanoid receptors involved in cultured human iridal melanocyte stimulation. Experimental Eye Research 2001 73 1 93 100 2-s2.0-0034769544 10.1006/exer.2001.1011 (Pubitemid 32977968)
25. Hu D. N., Wakamatsu K., Ito S., McCormick S. A., Comparison of eumelanin and pheomelanin content between cultured uveal melanoma cells and normal uveal melanocytes. Melanoma Research 2009 19 2 75 79 2-s2.0-65449154005 10.1097/CMR.0b013e328329ae49
26. Soulieres D., Rousseau A., Deschenes J., Tremblay M., Tardif M., Pelletier G., Characterization of gangliosides in human uveal melanoma cells. International Journal of Cancer 1991 49 4 498 503 2-s2.0-0025992296
27. Daniels K. J., Boldt H. C., Martin J. A., Gardner L. M., Meyer M., Folberg R., Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Laboratory Investigation 1996 75 1 55 66 2-s2.0-0029950678 (Pubitemid 26250273)
28. Zhou J. J., Xie G. R., Yan X. J., Phytochemistry of Chinese Traditional Medicine 2004 Beijing, China Chemical Industry Press
29. Shen Y. J., Pharmacology of Chinese Traditional Medicine 2002 Beijing, China People's Medical Publishing House
30. Boyd S. R., Tan D. S. W., de Souza L., Neale M. H., Myatt N. E., Alexander R. A., Robb M., Hungerford J. L., Cree I. A., Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. British Journal of Ophthalmology 2002 86 4 440 447 2-s2.0-0036216639 10.1136/bjo.86.4.440 (Pubitemid 34293295)
31. Sheidow T. G., Hooper P. L., Crukley C., Young J., Heathcote J. G., Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. British Journal of Ophthalmology 2000 84 7 750 756 2-s2.0-0033921038 10.1136/bjo.84.7.750 (Pubitemid 30438555)
32. Missotten G. S. O., Notting I. C., Schlingemann R. O., Zijlmans H. J., Lau C., Eilers P. H. C., Keunen J. E. E., Jager M. J., Vascular endothelial growth factor A in eyes with uveal melanoma. Archives of Ophthalmology 2006 124 10 1428 1434 2-s2.0-33749342662 10.1001/archopht.124.10.1428 (Pubitemid 44537143)
33. Boyd S. R., Tan D., Bunce C., Gittos A., Neale M. H., Hungerford J. L., Charnock-Jones S., Cree I. A., Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. British Journal of Ophthalmology 2002 86 4 448 452 2-s2.0-0036221217 10.1136/bjo.86.4.448 (Pubitemid 34293296)
34. Calipel A., Mouriaux F., Glotin A. L., Malecaze F., Faussat A. M., Mascarelli F., Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. Journal of Biological Chemistry 2006 281 14 9238 9250 2-s2.0-33646907501 10.1074/jbc.M600228200 (Pubitemid 43864639)
35. Zuidervaart W., van Nieuwpoort F., Stark M., Dijkman R., Packer L., Borgstein A. M., Pavey S., van der Velden P., Out C., Jager M. J., Hayward N. K., Gruis N. A., Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. British Journal of Cancer 2005 92 11 2032 2038 2-s2.0-21244489514 10.1038/sj.bjc.6602598 (Pubitemid 40897426)
36. Pópulo H., Soares P., Rocha A. S., Silva P., Lopes J. M., Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Research 2010 20 2 107 117 2-s2.0-77949545648 10.1097/CMR. 0b013e32832ccd09
37. Saraiva V. S., Caissie A. L., Segal L., Edelstein C., Burnier M. N. Jr., Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Research 2005 15 4 245 250 2-s2.0-23744472959 10.1097/00008390-200508000-00003 (Pubitemid 41127459)
38. Yan D., Zhou X., Chen X., Hu D. N., Dong X. D., Wang J., Lu F., Tu L. L., Qu J., MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Investigative Ophthalmology and Visual Science 2009 50 4 1559 1565 2-s2.0-64049119151 10.1167/iovs.08-2681